Who Paid My Doc
Relievant Medsystems, Inc.
MN, United States
CMS manufacturer 100000511825
General payments
$5,269,558
Research payments
$2,274,941
Ownership & investment interest
$686,567
Through program year 2023, Relievant Medsystems, Inc. reported paying $5,269,558 in general payments and $2,274,941 in research payments to U.S. physicians, teaching hospitals and other recipients.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | General | $2,122,684 | 14,233 |
| 2023 | Research | $156,529 | 65 |
| 2022 | General | $1,660,528 | 7,636 |
| 2022 | Research | $302,879 | 56 |
| 2021 | General | $741,406 | 4,652 |
| 2021 | Research | $175,676 | 62 |
| 2020 | General | $203,022 | 1,110 |
| 2020 | Research | $111,001 | 33 |
| 2019 | General | $541,918 | 1,257 |
| 2019 | Research | $1,528,855 | 67 |
Breakdown
Each share is of this company’s general payments naming a product in 2023. A payment can name up to five products, so these amounts overlap.
The top 5 of 90 specialties; each share is of this company’s general payments to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of this company’s general payments in 2023 where a state was reported.
Records
28,888 general · 283 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.